Abstract

Pre-eclampsia is a multi-systemic disorder whose cause remains unknown and is unique to human pregnancy. It is the major culprit in many births related adverse outcomes including intrauterine growth restriction. In this study, we observed the demographics, mode of delivery and pregnancy outcome of 49 patients that were admitted to our hospital with severe pre-eclampsia and IUGR. Most common age group of study subjects were found to be between 18-25 years (n = 22) while pregnancies were usually terminated after crossing 34 weeks gestation (n = 22). More than half the patients had to undergo caesarian sections (n = 27) followed by spontaneous vaginal delivery in 19 cases. Eleven cases needed medications for termination of pregnancy using mifepristone alone (9.1%), mifepristone followed by misoprostol (63.6%); and intrauterine catheter in combination with mifepristone or misoprostol (27.3%). A minimum of four hours and a maximum of 49 hours were spent between induction of labor and the delivery of the fetus. The overall survival rate of the fetuses was 77.6%. If predicted early and managed adequately, feto-maternal morbidity and mortality can be reduced among severe cases of pregnancy with intrauterine growth restriction.

Keywords: Early; Third Trimester Termination; Preeclampsia; IUGR

References

1. Murphy DJ and Stirrat GM. “Mortality and morbidity associated with early-onset preeclampsia”. Hypertension in Pregnancy2 (2000): 221-231.
2. Sibai B., et al. “Pre-eclampsia”. The Lancet9461 (2005): 785-799.
3. Crispi F., et al. “Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction”. American Journal of Obstetrics and Gynecology1 (2006): 201-207.
4. Ness RB and Sibai BM. “Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia”. American Journal of Obstetrics and Gynecology1 (2006): 40-49.
5. Crispi F., et al. “Predictive value of angiogenic factors and uterine artery Doppler for early‐versus late‐onset pre‐eclampsia and intrauterine growth restriction”. Ultrasound in Obstetrics and Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology3 (2008): 303-309.
6. Odendaal HJ and Pattinson RC. “Aggressive or Expectant Management for Patients with Severe Preeclampsia Between 28-34 weeks gestation: A Randomaized Control Trial”. Obstetrics and Gynecology 1070 (1990).
7. Nankali A., et al. “Maternal complications associated with severe preeclampsia”. The Journal of Obstetrics and Gynecology of India2 (2013): 112-115.
8. Witlin AG., et al. “Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24- and 33-weeks’ gestation”. American journal of obstetrics and gynecology 3 (2000): 607-611.
9. Mylonas I and Friese K. “Indications for and risks of elective cesarean section”. Deutsches Ärzteblatt International29-30 (2015): 489.
10. Sharma D., et al. “Comparison of mifepristone combination with misoprostol and misoprostol alone in the management of intrauterine death”. Taiwanese Journal of Obstetrics and Gynecology3 (2011): 322-325.
11. Chen W., et al. “A systematic review and network meta‐analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour”. BJOG: An International Journal of Obstetrics and Gynaecology3 (2016): 346-354.
12. Sibai BM., et al. “Maternal and perinatal outcome of conservative management of severe preeclampsia in mid trimester”. American Journal of Obstetrics and Gynecology1 (1985): 31-37.

Citation

Citation: Aklima Sultana Liza., et al. “Early Third Trimester Termination of Pregnancy in Case of Severe Preeclampsia with IUGR". Acta Scientific Gastrointestinal Disorders 5.8 (2022): .

Copyright

Copyright: © 2022 Aklima Sultana Liza., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.